

**Table 3 Demographic, Treatment, and Health Characteristics of SJLIFE Sample (n=897)<sup>a</sup>**

Variable	Short Sleep Duration n=400	Typical Sleep Duration n=495	P <sup>c</sup>
	<b>M (SD)</b>	<b>M (SD)</b>	
Age at evaluation, years	35.1 (8.5)	33.8 (9.2)	0.0397
Age at diagnosis, years	8.6 (5.7)	8.8 (5.6)	0.5239
BMI, amputation adjusted (kg/m <sup>2</sup> )	29.4 (7.5)	28.2 (6.7)	0.0137
	<b>N (%)</b>	<b>N (%)</b>	
Sex			
Female	212 (53.0)	252 (50.9)	0.5337
Male	188 (47.0)	243 (49.1)	
Race/Ethnicity			
White, non-Hispanic	324 (81.0)	429 (86.7)	0.0211
Other	76 (19.0)	66 (13.3)	
Diagnosis			
Leukemia	150 (37.5)	220 (44.4)	0.0945
CNS tumor	24 (6.0)	42 (8.5)	
Non-CNS solid tumor	108 (27.0)	101 (20.6)	
Hodgkin lymphoma	51 (12.8)	66 (13.4)	
Non-Hodgkin lymphoma	28 (7.0)	28 (5.7)	
Ewing/osteosarcoma	32 (8.0)	29 (5.9)	
Other	7 (1.8)	8 (1.6)	
Radiation			
Cranial radiation			
≥ 20 Gy	58 (12.3)	80 (16.9)	0.5078
< 20 Gy	44 (11.5)	56 (11.9)	
No cranial radiation	285 (74.2)	335 (70.8)	
Chest radiation	72 (18.7)	111 (23.5)	0.0865
Abdominal radiation	67 (17.4)	95 (20.1)	0.3095
Neck radiation	65 (16.8)	109 (23.0)	0.0244
Chemotherapy			
High dose IV methotrexate	118 (29.5)	162 (32.7)	0.3005
Intrathecal methotrexate/cytarabine	167 (41.8)	225 (45.5)	0.2667
Corticosteroids	202 (50.5)	269 (54.3)	0.2522
Anthracyclines	246 (61.5)	320 (64.7)	0.3317
Alkylating agents (classic)	232 (58.0)	300 (60.6)	0.4299
Alkylating agents (heavy metal)	37 (9.3)	48 (9.7)	0.8206
Ifosfamide	29 (7.3)	37 (7.5)	0.8982
Physically inactive <sup>b,c</sup>	162 (47.7)	183 (42.2)	0.1279
Psychological distress <sup>d,c</sup>			
BSI anxiety	35 (10.6)	13 (3.4)	<0.0001
BSI depression	34 (10.3)	20 (5.2)	0.0100
Chronic conditions			
Cardiac conditions (Grade ≥2)	173 (43.3)	192 (38.8)	0.1768
Endocrine conditions (Grade ≥2)	223 (55.8)	225 (45.5)	0.0022
Pulmonary conditions (Grade ≥2)	121 (30.3)	114 (23.0)	0.0147
Renal conditions (Grade ≥2)	46 (11.5)	43 (8.7)	0.1621

	Neurologic conditions (Grade $\geq 2$ )	130 (32.5)	147 (29.7)	0.3671
	Gastrointestinal conditions (Grade $\geq 2$ )	148 (37.0)	130 (26.3)	0.0006
	Musculoskeletal conditions (Grade $\geq 2$ )	123 (30.8)	146 (29.5)	0.6839

CNS, central nervous system; GY, gray; IV, intravenous; BSI, Brief Symptom Inventory; M, mean; SD, standard deviation

<sup>a</sup> Participants with long sleep duration removed (n=14)

<sup>b</sup> Physically inactive was defined according to CDC criteria of 450 MET-minutes per week

<sup>c</sup> Psychological distress defined as T-score  $\geq 63$

<sup>d</sup> The following variables had >10% missing: physically inactive (n=121); anxiety and depression (n=182);

<sup>e</sup> Chi-square test or t-test for comparison of continuous variables between short and typical sleep duration groups, all tests were two-sided